☆ 4.8 Meeting Abstract

Nivolumab in sorafenib-experienced patients with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis: CheckMate 040 study

JOURNAL OF HEPATOLOGY (2017)

Get Full Text
Add to Collection

Journal

JOURNAL OF HEPATOLOGY
Volume 66, Issue 1, Pages S34-S35

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/S0168-8278(17)30329-X

Keywords

-

Categories

Gastroenterology & Hepatology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Medicine, General & Internal

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Sara A. Hurvitz, Roberto Hegg, Wei-Pang Chung, Seock-Ah Im, William Jacot, Vinod Ganju, Joanne Wing Yan Chiu, Binghe Xu, Erika Hamilton, Srinivasan Madhusudan, Hiroji Iwata, Sevilay Altintas, Jan-Willem Henning, Giuseppe Curigliano, Jose Manuel Perez-Garcia, Sung-Bae Kim, Vanessa Petry, Chiun-Sheng Huang, Wei Li, Jean-Sebastien Frenel, Silvia Antolin, Winnie Yeo, Giampaolo Bianchini, Sherene Loi, Junji Tsurutani, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortes

Summary: In the DESTINY-Breast03 trial, trastuzumab deruxtecan showed superior progression-free survival compared to trastuzumab emtansine in patients with HER2-positive metastatic breast cancer. The study aimed to compare the efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine. The results demonstrated that trastuzumab deruxtecan had the longest reported median progression-free survival and improved overall survival, reaffirming its role as the standard of care in the second-line setting.

LANCET (2023)

Add to Collection
Article Biology

Host developmental stages shape the evolution of a plant RNA virus

Izan Melero, Ruben Gonzalez, Santiago F. Elena

Summary: Viruses rely on hosts to complete their infectious cycle, and the developmental stage of the host plays a crucial role in host-virus interactions. This study showed that hosts in later developmental stages are more susceptible to severe infections. The genomic changes of the evolved viral lineages depended on the founder viral isolate and the developmental stage of the host.

PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2023)

Add to Collection
Article Cell Biology

A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors

Ignacio Melero, Tamara Tanos, Mariana Bustamante, Miguel F. Sanmamed, Emiliano Calvo, Irene Moreno, Victor Moreno, Tatiana Hernandez, Maria Martinez Garcia, Alejo Rodriguez-Vida, Josep Tabernero, Analia Azaro, Mariano Ponz-Sarvise, Iben Spanggaard, Kristoffer Rohrberg, Ernesto Guarin, Eveline Nuesch, Iakov I. Davydov, Chiahuey Ooi, Jose Duarte, Evelyne Chesne, Christine McIntyre, Maurizio Ceppi, Marta Canamero, Oliver Krieter

Summary: This first-in-human study evaluated the effectiveness of RO7122290, a bispecific fusion protein, in stimulating T cells for improved tumor cell killing in FAP-expressing tumors. The study involved administering escalating doses of RO7122290, both as a single agent and in combination with atezolizumab, to patients with advanced or metastatic solid tumors. The results showed promising pharmacokinetics and treatment-induced changes in peripheral and tissue biomarkers, supporting further evaluation of RO7122290 in combination with immune-oncology agents for solid tumor treatment.

SCIENCE TRANSLATIONAL MEDICINE (2023)

Add to Collection
Article Immunology

Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy

Beatris Mastelic-Gavillet, Apostolos Sarivalasis, Leyder Elena Lozano, Sebastien Lofek, Tania Wyss, Ignacio Melero, I. Jolanda M. de Vries, Alexandre Harari, Pedro Romero, Lana Elias Kandalaft, Selena Vigano

Summary: Chemotherapy leads to depletion and functional impairment of cDC1 in patients with ovarian cancer, but has minimal impact on lymphocytes and cDC1 in some patients. This study provides new insights for designing new vaccination strategies with consideration of chemotherapy timing.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection
Article Oncology

Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic

Maite Alvarez, Carmen Molina, Saray Garasa, Maria C. Ochoa, Maria E. Rodriguez-Ruiz, Gabriel Gomis, Assunta Cirella, Irene Olivera, Javier Glez-Vaz, Jose Gonzalez-Gomariz, Carlos luri-Rey, Arantza Azpilikueta, Elixabet Bolanos, Alvaro Teijeira, Pedro Berraondo, Marisol Quintero, Ignacio Melero

Summary: The poly I:C-based viral mimetic BO-112 has been found to effectively reduce tumor metastasis when intratumorally delivered, particularly when combined with systemic anti-PD-1 mAbs. This neoadjuvant immunotherapy approach relies on antigen-specific effector CD8 T cells and cDC1 antigen-presenting cells.

ONCOIMMUNOLOGY (2023)

Add to Collection
Article Oncology

Achievement of Complete Response and Drug-free Status by Atezolizumab Plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-stage Hepatocellular Carcinoma: A Multicenter Proof-of-Concept Study

Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, Kaoru Tsuchiya, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Naoshi Nishida, Chikara Ogawa, Tetsu Tomonari, Noriaki Nakamura, Hidekatsu Kuroda, Atsushi Takebe, Yoshifumi Takeyama, Masaaki Hidaka, Susumu Eguchi, Stephen L. Chan, Masayuki Kurosaki, Namiki Izumi

Summary: The concept of curative conversion by combining systemic therapy and locoregional therapy in intermediate-stage HCC has not been reported before. This study aimed to show the value of curative conversion in immunotherapy-treated HCC. The results showed that 35% of patients achieved CR through resection, ablation, or super selective TACE.

LIVER CANCER (2023)

Add to Collection
Review Oncology

Advances in Immunotherapy for Hepatocellular Carcinoma

Satoru Hagiwara, Naoshi Nishida, Masatoshi Kudo

Summary: Immunotherapy for hepatocellular carcinoma (HCC) is rapidly advancing, with a focus on analyzing the tumor immune environment and developing custom-made treatments. Understanding the immune environment of HCC is vital for selecting appropriate immune checkpoint inhibitors (ICIs) and managing their side effects. This summary aims to review the progress of immunotherapy in HCC and its implications for future treatment.

CANCERS (2023)

Add to Collection
Article Oncology

Non-Inflamed Tumor Microenvironment and Methylation/Downregulation of Antigen-Presenting Machineries in Cholangiocarcinoma

Naoshi Nishida, Tomoko Aoki, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Hiroshi Ida, Satoru Hagiwara, Yasunori Minami, Kazuomi Ueshima, Masatoshi Kudo

Summary: Cholangiocarcinoma (CCA) is a resistant cancer, and a majority of CCAs have a non-inflamed tumor phenotype resistant to treatment, including immune checkpoint inhibitors (ICIs). This study aimed to understand the molecular characteristics of non-inflamed CCAs. The genetic/epigenetic status of 36 CCAs was analyzed, and it was found that tumors with alterations in FGFR2 and IDH1/2 had a non-inflamed phenotype. Downregulation of genes involved in antigen presentation and DNA methylation were associated with the non-inflamed phenotype. These findings provide important insights for developing new strategies to treat CCA.

CANCERS (2023)

Add to Collection
Review Medicine, General & Internal

Contrast-Enhanced Harmonic Endoscopic Ultrasound-Guided Puncture for the Patients with Pancreatic Masses

Yasuo Otsuka, Ken Kamata, Masatoshi Kudo

Summary: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is a useful method for diagnosing pancreatic masses. The diagnostic performance of EUS-FNA can be improved by using contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS), which helps avoid fibrosis in the pancreatic mass. However, the effectiveness of CH-EUS-FNA is still a matter of debate, as only one out of eight studies showed improved sensitivity.

DIAGNOSTICS (2023)

Add to Collection
Article Medicine, General & Internal

Usefulness of the Measurement of Psoas Muscle Volume for Sarcopenia Diagnosis in Patients with Liver Disease

Takushi Manabe, Chikara Ogawa, Kei Takuma, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Koji Fujita, Joji Tani, Mitsushige Shibatoge, Asahiro Morishita, Masatoshi Kudo, Tsutomu Masaki

Summary: This study validated the assessment of sarcopenia using psoas muscle volume as a measure and found that sarcopenia was associated with shorter survival in patients with liver disease. The psoas muscle volume index (PMVI) may be useful in evaluating sarcopenia, including cases where sarcopenia cannot be diagnosed using the commonly used psoas muscle index (PMI).

DIAGNOSTICS (2023)

Add to Collection
Article Biochemistry & Molecular Biology

Oral administration of ovalbumin protects mice from concanavalin A-induced hepatitis through suppression of interferon-gamma responses

Tomohiro Watanabe, Kosuke Minaga, Hajime Honjo, Masatoshi Kudo

Summary: The liver showed hypo-responsiveness to antigens and high doses of orally-administered ovalbumin (OVA) generated unique CD4+ T cells and tolerogenic dendritic cells that can suppress Th1 responses. OVA administration at high doses inhibited hepatitis development in mice with OVA-specific CD4+ T cells, and this was associated with downregulation of Th1 responses. The results suggest that high-dose oral antigen administration can suppress Th1-mediated hepatitis in an antigen-non-specific manner.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2023)

Add to Collection
Article Medicine, Research & Experimental

Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies

Ignacio Melero, Maria C. Ochoa, Carmen Molina, Sandra Sanchez-Gregorio, Saray Garasa, Carlos Luri-Rey, Sandra Hervas-Stubbs, Noelia Casares, Edurne Elizalde, Gabriel Gomis, Assunta Cirella, Pedro Berraondo, Alvaro Teijeira, Maite Alvarez

Summary: NK cell reactivity against cancer is suppressed in the tumor microenvironment through the interaction of the inhibitory receptor NKG2A with non-classical MHC-I molecules. Injection of anti-NKG2A and anti-Qa-1(b) antibodies enhances the therapeutic effects of NK cells and shows partial efficacy against distant tumors. In experiments with human cancer cells expressing HLA-E, injection of activated allogeneic human NK cells and anti-NKG2A antibodies synergistically achieve therapeutic effects.

EMBO MOLECULAR MEDICINE (2023)

Add to Collection
Review Immunology

Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming

Carlos Luri-Rey, Gabriel Gomis, Javier Glez-Vaz, Almudena Manzanal, Ana Martinez Riano, Maria E. Rodriguez Ruiz, Alvaro Teijeira, Ignacio Melero

Summary: Antigen cross-priming of CD8+ T cells plays a critical role in the expansion and activation of these cells, and cytotoxic immune cells-mediated cell death is important for the cross-presentation of tumor antigens. Certain dendritic cells are essential for the cross-presentation of tumor antigens, while NK cells and CTL cells-mediated cell death is a prominent form of immunogenic cell death.

IMMUNOLOGICAL REVIEWS (2023)

Add to Collection
Review Oncology

Tips for Preparing and Practicing Thermal Ablation Therapy of Hepatocellular Carcinoma

Yasunori Minami, Tomoko Aoki, Satoru Hagiwara, Masatoshi Kudo

Summary: Thermal ablation therapy, including RFA and MWA, is a widely used treatment for hepatocellular carcinomas. It achieves good outcomes with minimal invasiveness. Successful thermal ablation therapy requires understanding the principles and characteristics of the treatment, assessing the benefits and risks, precise needle control and visualization, utilizing imaging guidance techniques, and evaluating therapeutic response. This overview provides essential information for the clinical application of thermal ablation.

CANCERS (2023)

Add to Collection
Article Oncology

Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update

Masatoshi Kudo

LIVER CANCER (2023)

Add to Collection
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.